Member Profile

Medigen Biotechnology Corp. (MBC) was established in late 1999. The company upholds the vision of “Innovations for a better life” focusing on the development of new therapies for liver diseases and cancers. MBC has now gradually developed into a comprehensive biopharmaceutical corporation with business fields covering cell therapy technology, new drug, molecular diagnostics, precision medicine, cell-based vaccine, biologics and ophthalmic drug.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2013 Medigen Biotechnology Corporation (MBC) liver cancer new drug OBP-301 (coop. with Oncolys BioPharma Inc.) obtained European patent.
   2014 MBC acquired Winston Pharma for drug production.
   2014 OBP-301 was approved by MFDS to start phase I/II trial of intermediate to advanced hepatocellular carcinoma in Korea.
   2015 PI-88 finished phase III treatments on all patients.
   2015 Nucleic Acid Test department became an independent company TBG Biotechnology Corp. (TBG).
   2016 Medigen’s liver cancer new drug OBP-301 licensed to Jiangsu Hengrui Medicine for the right of China, Hong Kong, and Macau.
   2016 Medigen and Oncolys decided to conduct melanoma and esophageal cancer indications on OBP-301.
   2017 PI-88 phase III trial result was disclosed on February, and it will be published in European Society for Medical Oncology (ESMO) this year.
   2017 OBP-301 enrolled first patient in melanoma phase II US trial.
   2018 Medigen collaborates with Evergreen Health Clinic and E-Da Cancer Hospital to apply for Natural Kill (NK) cell therapy treatment plan in Taiwan
   2019 Exclusive license agreement with Chugai Pharmaceutical Co., Ltd. concerning the development, manufacturing and marketing in Japan and Taiwan for OBP-301
   2019 Medigen has entered into exclusive license agreement with Japanese publicly listed company MEDINET to expand Gamma-delta T cell therapy market in Taiwan
   2019 Medigen and Cellxpert Beijing have entered into agreement under which Medigen will grant an exclusive worldwide license except Taiwan to Cellxpert for PI-88
   2020 Medigen has obtained approval from Ministry of Health and Welfare for Natural Kill (NK) cell therapy
   2020 Enrollment of first patient in phase II study of combination therapy with OBP-301 and radiotherapy in Japan
   2020 Medigen’s subsidiary, TBG Receives US FDA EUA for COVID-19 Nucleic Acid Test Kits
   2021 Submission of IND application with the TFDA for phase 1 clinical trial of Magicell-NK